Search Results

You searched for "pXS-4728"

• Pharmaxis to Receive £2.9m from Parkinson’s UK for Phase 2 Parkinson’s Disease Clinical Trial

  Ground-breaking Pharmaxis collaboration with Parkinson’s UK and leading neurologists to investigate PXS-4728 to treat patients at risk of Parkinson’s and other neurodegenerative diseases. The £2.9m funding comes...

  Read more about "Pharmaxis to Receive £2.9m from Parkinson’s UK for Phase 2 Parkinson’s Disease Clinical Trial"...

• Syntara doses first patient in Phase 2 trial of patients with sleep disorder at risk of Parkinson’s disease

  Clinical stage drug developer Syntara1 today announced that the first patient has been dosed in its randomised double-blind placebo controlled Phase 2 study of the Syntara...

  Read more about "Syntara doses first patient in Phase 2 trial of patients with sleep disorder at risk of Parkinson’s disease"...

• Analyst Coverage

  Research reports on Pharmaxis issued by the following organisations are listed below:  Firm Analyst Contact   Mark Pachacz (editor)   info@bioshares.com.au     Anubhav Saxena   asaxena@bellpotter.com.au   Alfred Chan Emerald Financial   alfred.chan@emeraldfinancial.com.au   Derek Jellinek Iain Wilkie Scott Power   derek.jellinek@morgans.com.au   Chris Kallos   chris.kallos@mstaccess.com.au   Dennis Hulme   dhulme@taylorcollison.com.au 01/11/2023 1Q: Refocused Business Cutting Expenses,...

  Read more about "Analyst Coverage"...